



PTO/SB/08A/B (09-06)
 Approved for use through 03/31/2007. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	08/444,790-Conf. #5612
				Filing Date	May 19, 1995
				First Named Inventor	Manfred Brockhaus
				Art Unit	1646
				Examiner Name	Z. Howard
Sheet	1	of	1	Attorney Docket Number	01017/40451B

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
ZH	A64	5,428,130			
ZH	A65	5,843,791			
ZH	A66	6,224,867			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
ZH	B42	EP-0 394 827	10-31-1990			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
ZH	C157	FOLKS et al., Tumor necrosis factor α induces expression of human immunodeficiency virus in a chronically infected T-cell clone, PNAS, 86:2365-8 (1989).			
ZH	C158	LEE, Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase, Science, 239:1288-1291 (1988).			
ZH	C159	MORELAND et al., Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein, New England Journal of Medicine, 337:141-147 (1997).			
ZH	C160	SANDBORN et al., Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial, Gastroenterol., 121:1088-94 (2001).			
ZH	C161	WOZNEY, Using purified protein to clone its genes, Methods in Enzymology, 182:738-751 (1990).			
ZH	C162	Inflammation & Infection: Rheumatoid Arthritis, Drug & Market Development, 67-70 (2003).			
ZH	C163	Letter to the EPO with new Auxiliary request 3 in appeal proc. against EP 0 471 701.			
ZH	C164	Notification of the Examiner during the prosecution of EP 99100703.0.			
ZH	C165	Zavoico, Drug & Market Development, 10(7):235-243 (1999).			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Zachary Howard/	Date Considered	02/02/2007
-----------------------	------------------	--------------------	------------

957329



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	08/444,790
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1646
				Examiner Name	Z. Howard
Sheet	1	of	2	Attorney Docket Number	01017/40451B

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
ZH	C162	Mohler et al., Soluble Tumor Necrosis Factor (TNF) Receptors are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists. <i>J. Immunol.</i> , 151:1548-1561 (1993)		
	C163	Sell, Immunology, Immunopathology and Immunity, 4 th Edition, Elsevier Science Publishing Co., New York, 1987, at pp. 85-91		
	C164	Bringman, Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes. <i>Hybridoma</i> , 6(5):489-507 (1987)		
	C165	Paul et al., Fundamental Immunology, 2 nd Edition, Paul, ed., Raven Press, New York, 1989, at pp. 679-701 and pp. 735-764.		
	C166	Smith et al., A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins, <i>Science</i> , 248:1019-1023, (1990)		
	C167	Wingfield et al., Tumour Necrosis Factor is a Compact Trimer, <i>FEBS Lett.</i> 211: 179-84 (1987)		
	C168	Smith and Baglioni, The Active Form of Tumor Necrosis Factor is a Trimer. <i>J. Biological Chemistry</i> , 262:6951-4 (1987)		
	C169	Larsson and Mosbach, Affinity Precipitation of Enzymes <i>FEBS Lett.</i> 98(2):333-338 (1979)		
	C170	Irwin and Tipton, Chapter 22, "Affinity Precipitation Methods" in <i>Methods in Mol. Bio.</i> , 59:217 (1996)		
	C171	Kohno et al., Presentation 1495, poster 271 presented at American College of Rheumatology Annual Meeting, November 13-17, 2005, San Diego, CA		
↓	C172	Klein, Immunology, 1 st Edition, Klein ed., Blackwell Scientific Publications, Cambridge, MA 1990 at pp. 446-447		
Examiner Signature		/Zachary Howard/		Date Considered 02/02/2007

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	08/444,790
				Filing Date	May 19, 1995
				First Named Inventor	Brockhaus
				Art Unit	1646
				Examiner Name	Z. Howard
Sheet	2	of	2	Attorney Docket Number	01017/40451B

ZH	C173	Byrn et al., Biological properties of a CD4 Immunoaderhin, Nature, 344:667-670 (April 1990)		
	C174	Trauneeher et al., Highly Efficient Neutralization of HIV with Recombinant CD-4-Immunoglobulin Molecules, Nature 339:68-70, 1989		
	C175	Capon, Designing CD4 Immunoaderhensions for AIDS Therapy, Nature, 337:525-531 (1989)		
	C176	Barone et al., Comparative Analysis of the Ability of Entanercept and Inflixamab to Lyse TNF-Expressing Cells in a Complement-Dependent fashion, Arthritis Rheum., v42(9) supplement, September 1999		
↓	C177	Khare et al, Poster 715 presented at the Annual Meeting of the Society for Investigative Dermatology (SID), May 3-5, 2006, Philadelphia, PA		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Zachary Howard/	Date Considered	02/02/2007
--------------------	------------------	-----------------	------------